Jul 8, 2026
Lior Shaltiel, CEO of NurExone, is addressing the unmet needs of those with spinal cord injuries, as current therapies only treat symptoms and do not regenerate damaged nerves from accidents or disease. The NurExone technology aims to stimulate nerve growth by targeting a protein that inhibits cell proliferation. Using...
Jul 8, 2026
Lior Shaltiel, CEO of NurExone, is addressing the unmet needs of those with spinal cord injuries, as current therapies only treat symptoms and do not regenerate damaged nerves from accidents or disease. The NurExone technology aims to stimulate nerve growth by targeting a protein that inhibits cell proliferation. Using...
Mar 4, 2025
Olivier Visa, President and CEO of Evergen specializes in developing and manufacturing biomaterials for use in regenerative medicine. These customized biomaterial solutions use xenografts, allografts, and emerging technologies inside and outside the body with applications in wound healing, cardiac, dental, breast,...
Mar 4, 2025
Olivier Visa, President and CEO of Evergen specializes in developing and manufacturing biomaterials for use in regenerative medicine. These customized biomaterial solutions use xenografts, allografts, and emerging technologies inside and outside the body with applications in wound healing, cardiac, dental, breast,...
Feb 5, 2024
Chris Paradise, VP of Research and Development at Rion, is taking an acellular approach to developing next-generation regenerative medicines to treat degenerative diseases. The proprietary Rion system PEP, purified exosome product, uses extracellular vesicles or exosomes isolated from human blood platelets to send...